Metastatic Breast Cancer
Conference Coverage
Key research on TNBC: Top five picks from SABCS
A study on the impact of platinum therapy on long-term TNBC outcomes ranks among the most popular.
News
Terminally ill cancer patients struggle to access psilocybin
“I think what we have here is a confluence of events that are driving toward the mandatory opening of a path to access psilocybin for therapeutic...
Conference Coverage
Capivasertib/fulvestrant improves progression free survival in breast cancer
The combination of the investigational AKT inhibitor capivasertib and estrogen receptor antagonist fulvestrant, doubled progression-free survival...
Conference Coverage
Gene signature may spare some breast cancer patients from radiation
The POLAR 16-gene mRNA signature accurately identified patients who were unlikely to benefit from radiotherapy after breast-conserving surgery.
Conference Coverage
High response rates with T-DXd in early HER2-low breast cancer
Nearly 70% of patients with hormone receptor-positive breast cancers with low levels of HER2 had pathological response to the antibody-drug...
Conference Coverage
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1...
Conference Coverage
Chemotherapy meets its match against aggressive ER+/HER2– breast cancers
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
Conference Coverage
Potential cause of worse outcomes among Black breast cancer patients found
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
Opinion
Diagnosed too late
We take a course in giving bad news, but every doctor has his or her own approach.
News
Managing trastuzumab deruxtecan adverse events in the real world
Doctor says real-world toxicity experience has been worse than clinical trial data.